It’s just common sense, IMO, that ribavirin should be included for cirrhotic patients if there is any doubt at all about its utility. (This is a separate matter from 8w-vs-12w dosing or the addition of a third DAA by GILD.)
Bottom line (re-iterated): I think it will be hard for GILD (or anyone else) to top the data from TURQUOISE-2.
Market Data 
Markets 
AI
